medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


Prevención y control de neoplasias asociadas a VPH en grupos de alto riesgo de la Ciudad de México: el Estudio Condesa

Lazcano-Ponce E, Salmerón J, González A, Allen-Leigh B, León-Maldonado L, Magis C, Aranda-Flores C, Conde-González C, Portillo-Romero AJ, Yunes-Díaz E, Rivera-Rivera L, Vargas G, Nyitray AG, Giuliano AR

Idioma: Ingles.
Referencias bibliográficas: 55
Paginas: 703-712
Archivo PDF: 444.07 Kb.


RESUMEN

Objetivo. Evaluar la efectividad de una estrategia combinada de vacunación contra el virus de papiloma humano (VPH) y tamizaje de VPH de alto riesgo para reducir neoplasias anogenitales y orofaringeas entre hombres que tienen sexo con hombres, personas con VIH, personas en situación de calle, mujeres transgénero, trabajadoras sexuales y víctimas de violación. Material y métodos. Este estudio evaluará la efectividad de una estrategia combinada de vacunación y tamizaje para reducir la ocurrencia de neoplasias intraepiteliales cervicales grado 2+ o neoplasias intraepiteliales anales grado NIA2+ utilizando Kaplan-Meier. Se evaluará tiempo de resultados positivos para tipos específicos de VPH anogenital a incidencia de lesiones anogenitales con ese tipo de VPH. Resultados. Las personas vacunadas contra VPH y con tamizaje de VPH tendrán menor prevalencia e incidencia de infecciones por VPH y por ende menor frecuencia de lesiones anogenitales y orofaringeas relacionadas con VPH. Conclusiones. Este estudio generará evidencia científica sobre la efectividad de una estrategia combinada de vacunación y tamizaje para reducir la carga de neoplasias asociadas al VPH.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Combes JD, Clifford GM, Egger M, Cavassini M, Hirsch HH, Hauser C, et al. Human papillomavirus antibody response following HAART initiation among MSM. AIDS. 2017;31(4):561-9. https://doi.org/10.1097/ QAD.0000000000001354

  2. Raghavendran A, Hernandez AL, Lensing S, Gnanamony M, Karthik R, Sivasubramanian M, et al. Genital Human Papillomavirus Infection in Indian HIV-Seropositive Men Who Have Sex With Men. Sex Transm Dis. 2017;44(3):173-80. https://doi.org/10.1097/OLQ.0000000000000564

  3. Nyitray AG, da Silva RJ, Baggio ML, Lu B, Smith D, Abrahamsen M, et al. The prevalence of genital HPV and factors associated with oncogenic HPV among men having sex with men and men having sex with women and men: the HIM study. Sex Transm Dis. 2011;38(10):932-40. https://doi. org/10.1097/OLQ.0b013e31822154f9

  4. Peng RR, Li HM, Chang H, Li JH, Wang AL, Chen XS. Prevalence and genotype distribution of cervical human papillomavirus infection among female sex workers in Asia: a systematic literature review and metaanalysis. Sex Health. 2012;9(2):113-9. https://doi.org/10.1071/SH11066.

  5. Loverro G, Di Naro E, Caringella AM, De Robertis AL, Loconsole D, Chironna M. Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy. Sex Transm Infect. 2016;92(1):67-9. https:// doi.org/10.1136/sextrans-2014-051987

  6. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, et al. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919-20. https://doi.org/10.1016/S0140-6736(15)00757-6

  7. Bogani G, Martinelli F, Ditto A, Signorelli M, Taverna F, Lombardo C, et al. The association of pre-treatment HPV subtypes with recurrence of VIN. Eur J Obstet Gynecol Reprod Biol. 2017;211:37-41. https://doi. org/10.1016/S0140-6736(15)00757-6

  8. Wakeham K, Kavanagh K, Cuschieri K, Millan D, Pollock KG, Bell S, et al. HPV status and favourable outcome in vulvar squamous cancer. Int J Cancer. 2017;140(5):1134-46. https://doi.org/10.1002/ijc.30523

  9. Feber A, Arya M, de Winter P, Saqib M, Nigam R, Malone PR, et al. Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancer. Clin Cancer Res. 2015;21(5):1196-206. https://doi. org/10.1158/1078-0432.CCR-14-1656

  10. Keglovitz K, Richardson AD, Lancki N, Walsh T, Schneider JA. Anal squamous intraepithelial lesions and HPV among young black men who have sex with men. LGBT Health 2017;4(1):72-74. https://doi.org/10.1089/ lgbt.2016.0049

  11. Palefsky JM. Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era. Curr Opin HIV AIDS. 2017;12(1):26-30.

  12. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):122-37. https://doi.org/10.3322/caac.21389

  13. Clemente N, Alessandrini L, Vaccher E, De Paoli A, Buttignol M, Canzonieri V, et al. Multiple preinvasive and invasive HPV-related lesions of the anogenital tract in a female patient with HIV infection: A case report. Medicine (Baltimore). 2017;96(4):e5948. https://doi.org/10.1097/ MD.0000000000005948

  14. Rob F, Tachezy R, Pichlík T, Rob L, Kružicová Z, Hamšíková E, et al. High prevalence of genital HPV infection among long-term monogamous partners of women with cervical dysplasia or genital warts-Another reason for HPV vaccination of boys. Dermatol Ther. 2017;30(1). https:// doi.org/10.1111/dth.12435

  15. Colon-Lopez V, Ortiz AP, Soto-Salgado M, Torres-Cintrón M, Perez N, Mercado-Acosta JJ, et al. Survival from anal cancer among Hispanics- Puerto Rico, 2000-2007. J Gastrointest Cancer. 2014;45(2):234-8. https:// doi.org/10.1007/s12029-014-9607-x

  16. Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIVpositive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31(2):96-9.

  17. Lowy DR. HPV vaccination to prevent cervical cancer and other HPVassociated disease: from basic science to effective interventions. J Clin Invest. 2016;126(1):5-11. https://doi.org/10.1172/JCI85446

  18. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016;63(4):519-27. https://doi.org/10.1093/cid/ciw354

  19. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cáncer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58:211-219. https://doi.org/10.21149/spm.v58i2.7790

  20. Bouchard-Fortier G, Hajifathalian K, McKnight MD, Zacharias DG, Gonzalez-Gonzalez LA. Co-testing for detection of high-grade cervical intraepithelial neoplasia and cancer compared with cytology alone: a meta-analysis of randomized controlled trials. J Public Health (Oxf). 2014;36(1):46-55. https://doi.org/10.1093/pubmed/fdt057

  21. Lazcano-Ponce E, Lőrincz AT, Torres L, Salmerón J, Cruz A, Rojas R, et al. Specimen self-collection and HPV DNA screening in a pilot study of 100,242 women. Int J Cancer. 2014;135(1):109-16. https://doi.org/10.1002/ ijc.28639

  22. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmerón J, Uribe P, Velasco-Mondragón E. et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community- based randomised controlled trial. Lancet. 2011;378(9806):1868-73. https://doi.org/10.1002/ijc.28639

  23. Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control. 2010;21(10):1693-700. https://doi.org/10.1007/s10552-010-9598-2

  24. Torres-Ibarra L, Lazcano-Ponce E, Franco EL, Cuzick J, Hernández-Ávila M, Lorincz A, et al. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex. 2016;58(2):197-210. https://doi.org/10.21149/spm.v58i2.7789

  25. Advisory Committee on Immunization Practices. IPVS Policy statement on safety of HPV vaccines. Papillomavirus Res. 2016;2:9-10. https://doi. org/10.1016/j.pvr.2015.11.001

  26. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, et al. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919-20. https://doi.org/10.1016/S0140-6736(15)00757-6

  27. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Recommended Immunization Schedule for Adults Aged 19 Years or Older. United States: CDC, 2018. [cited October 15, 2018]. Available at: http://www.cdc.gov/vaccines/schedules/ hcp/imz/adult-conditions-shell.html

  28. Stier EA, Chigurupati NL, Fung L. Prophylactic HPV vaccination and anal cancer. Hum Vaccin Immunother. 2016;12(6):1348-51. https://doi.org/1 0.1080/21645515.2016.1149274

  29. Toft L, Tolstrup M, Storgaard M, Ostergaard L, Søgaard OS. Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sex Health. 2014;11(6):511-23. https://doi.org/10.1071/SH14015

  30. Li X, Stander MP, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. BMC Infect Dis. 2015;15:566. https://doi.org/10.1186/s12879-015-1295-z

  31. Deshmukh AA, Chhatwal J, Chiao EY, Nyitray AG, Das P, Cantor SB. Long-Term Outcomes of Adding HPV Vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men. Clin Infect Dis. 2015;61(10):1527-35. https://doi.org/10.1093/cid/civ628

  32. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23. https://doi.org/10.1016/j.vaccine. 2012.07.055

  33. Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine. 2013;31(37):3863-71. https://doi.org/10.1016/j.vaccine.2013.06.064

  34. Stanley M, Pinto LA, Trimble C. Human papillomavirus vaccines immune responses. Vaccine 2012;30 Suppl 5:F83-7. https://doi.org/10.1016/j. vaccine.2012.04.106

  35. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-9. https://doi.org/10.1097/01.inf.0000253970.29190.5a

  36. Kane MA, Serrano B, de Sanjosé S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30(Suppl 5):F192-200. https://doi.org/10.1016/j.vaccine.2012.06.075

  37. Franco EL. Bernard Duval: the architect of Quebec’s HPV immunization programme. Public Health Genomics. 2009;12(5-6):261-3. https://doi. org/10.1159/000214916

  38. Hernández-Ávila M, Torres-Ibarra L, Stanley M, Salmerón J, Cruz-Valdez A, Muñoz N, et al. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother. 2016;12(1):30-8. https://doi.org/10.1080/21645515.2015.1058458

  39. Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine. 2014;32(6):725-32. https://doi.org/10.1016/j.vaccine.2013.11.059

  40. Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 2011;305(14):1424-31. https://doi.org/10.1001/jama.2011.407

  41. Vassilakos P, Untiet S, Petignat P. Cervical cancer prevention in Switzerland: the challenges of the vaccine era. Rev Med Suisse. 2012;8(359):2015-6.

  42. Wheeler C. Numbers game: Researchers explore whether fewer than 3 doses of HPV vaccine are effective. Cancer. 2016;122(1):11-2. https://doi. org/10.1002/cncr.29815

  43. Juárez-Figueroa LA, Uribe-Salas FJ, Conde-González CJ, Sánchez- Alemán MA. Serological markers of hepatitis B and C, and HIV in La Calera and Cuambio, Guerrero, Mexico. Salud Publica Mex 2011;53(supl 1):S32-S36.

  44. Gutiérrez JP, Sucilla-Pérez H, Conde-González CJ, Izazola JA, Romero- Martínez M, Hernández-Ávila M. Decrease of HCV seroprevalence in Mexico: Results from the National Health and Nutrition Survey 2012. Salud Publica Mex. 2016;58:25-32. https:// doi.org/10.21149/spm. v58i1.7664

  45. Yáñez-Alvarez I, Conde-Glez CJ, Uribe-Salas FJ, Olamendi-Portugal ML, García-Cisneros S, Sánchez-Alemán MA. Maternal/child seroprevalence of antibodies against Treponema pallidum at four general hospitals in the state of Morelos, Mexico. Arch Med Res. 2012;43:571-7. https://doi. org/10.1016/j.arcmed.2012.10.001

  46. Uribe-Salas F, Palma-Coca A, Sánchez-Alemán MA, Olamendi M, Juárez- Figueroa L, Conde-Glez CJ. Population-based prevalence of antibodies against herpes simplex virus type 2 and socio-demographic characteristics in Mexico. Trans Roy Soc Trop Med Hyg. 2009;103:151-8.

  47. Moncada J, Schachter J, Liska S, Shayevich C, Klausner JD. Evaluation of self-collected glans and rectal swabs from men who have sex with men for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of nucleic acid amplification tests. J Clin Microbiol 2009;47:1657-1662. https://doi.org/10.1128/JCM.02269-08

  48. Brown B, Poteat T, Marg L, Galea JT. Human papillomavirus-related cancer surveillance, prevention, and screening among transgender men and women: neglected populations at high risk. LGBT Health. 2017;4(5):315-9. https://doi.org/10.1089/lgbt.2016.0142

  49. Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487-500. https://doi.org/10.1016/S1470- 2045(12)70080-3

  50. de Sanjose S, Wheeler CM, Quint WGV, Hunt WC, Joste NE, Alemany L, et al. Age-specific occurrence of HPV16- and HPV18-related cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(7):1313-8. https://doi. org/10.1158/1055-9965.EPI-13-0053

  51. Hammer A, Rositch A, Qeadan F, Gravitt PE, Blaakaer J. Age-specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta-analysis. Int J Cancer. 2016;138(12):2795-803. https://doi. org/10.1002/ijc.29959

  52. Bosch FX, Robles C, Díaz M, Arbyn M, Baussano I, Clavel C, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13(2):119-32. https://doi.org/10.1038/nrclinonc. 2015.146

  53. Wigle J, Coast E, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811-7. https:// doi.org/10.1016/j.vaccine.2013.06.016

  54. Curotto M, Zalacaín-Colombo J, Paolino M, Arrossi S. Adopción e implementación del ofrecimiento de la autotoma VPH por agentes sanitarios en Jujuy, Argentina. Salud Publica Mex. 2018;60. https://doi. org/10.21149/8854

  55. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, et al. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919-20. https://doi.org/10.1016/S0140-6736(15)00757-6




2020     |     www.medigraphic.com